Cross-linked enzymatically controlled drug release
US5603956A · kind A · utility
31Cited by
18References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 1994 |
| Grant date | Feb 18, 1997 |
| Priority date | — |
| Expiry date | Jun 16, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2068
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, .alpha.-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the .alpha.-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of .alpha.-amylase in the tablet. The amount of .alpha.-amylase is defined in terms of Enzyme Units.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.